Use of etv3 or etv6 inhibitors for blocking the differentiation of monocytes into dendritic cells

In inflamed tissues, monocytes differentiate into macrophages (mo-Mac) or dendritic cells (mo-DC). In chronic non-resolving inflammation, mo-DC are major drivers of pathogenic events. Manipulating monocyte differentiation would therefore represent an attractive therapeutic strategy. Here the inventors show that the transcriptional repressors ETV3 and ETV6 control monocyte differentiation into mo-DC. To validate the physiological relevance of these findings, the inventors generated mice deficient for ETV6 in monocytes. Deficient mice show spontaneous expression of interferon-stimulated genes, confirming that ETV6 regulates interferon responses in vivo. Furthermore, deficient mice display impaired mo-DC differentiation during peritonitis and less severe symptoms in experimental autoimmune encephalomyelitis. The findings identify ETV3 and ETV6 as a therapeutic target to redirect monocyte differentiation in inflammatory disorders.

Patent Application number: European Procedure (Patents) (EPA) - 01 Sept. 2021 - 21 306 195.5
Inventors:
SEGURA Elodie,VILLAR Javiera

Reference:

BIO21335-T1

Business Developper
contact
Inserm Transfert
Business Developer
Patent filling date: 2021-09-01

You might also be interested in